950210 — Prestige Biopharma Share News
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- $10.22m
Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
Australia's Imagion Biosystems rises on MOU for cancer detection device
Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
Brief: Prestige Biopharma Signs Pharmaceutical Contract Manufacturing Agreement With Benevira Inc
Development Of COVID-19/Influenza Combo Vaccine
Result Of Phase 3 Study For Prestige Biopharma's Herceptin Biosimilar, Hd201(Tuznue®), Published In JAMA Oncology
Brief: Prestige Biopharma & Dr. Reddy's Announce Partnership To Commercialize Trastuzumab Biosimilar In Some Countries In Latin America & Southeast Asia
Second S.Korean deal to produce Russia's Sputnik V (updated)
S.Korean consortium to produce 100 mln doses a month of Russia's Sputnik V vaccine